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Abstract
Expression of the CD40 ligand (CD40L) on tumors can activate host immune systems and produce antitumor effects against the tumors. To deliver
theCD40L gene efficiently, we evaluated the efficiency of transduction of different serotypes of adeno-associated virus (AAV) vectors in lung cancer
A549 cells and compared the transduction efficiency of a conventional AAV vector with that of self-complementary AAV (scAAV) vectors as well.
We determined that serotype AAV2/5 transduced A549 cells much more efficiently than serotypes AAV2/1, AAV2/2, AAV2/6, AAV2/7, AAV2/8,
AAV2/9 and AAV2/10. And the transduction efficiency of scAAV2/5 was significantly higher than conventional AAV2/5. Furthermore, pre-
treatment with carboplatin, which is a chemotherapeutic agent used in lung cancer chemotherapy, substantially increased AAV-mediated transgene
expression. The scAAV2/5 vectors encoding human CD40L were used to tranduce CD40L into A549 cells, which were then co-cultivated with
immature human dendritic cells (DCs). Interleukin 12 (IL-12) that was released was measured in the culture supernatant. Specificity of the
immunostimulatory effect of CD40L was confirmed by blocking with a monoclonal antibody binding to human CD40L. The in vivo antitumor
activity was evaluated in BALB/c nude mice bearing A549 lung cancer. scAAV2/5-CD40L showed significant inhibitory effects on the growth of
transplanted tumor cells as compared with control group. These studies suggest that recombinant AAV2/5-CD40L may provide an effective form of
therapy for lung cancer.
© 2007 Elsevier Inc. All rights reserved.Keywords: Adeno-associated virus; Serotype; Transduction efficiency; Lung neoplasms; CD40 ligand (CD40L); Dendritic cellsIntroduction
Lung carcinoma is the leading cause of malignancy-related
mortality. Non-small cell lung cancer now accounts for about
three-quarters of all cases of lung cancer, which is primarily due
to a propensity to metastasize as well as resistance to chemo-
therapy and radiation (Singh and Dhindsa, 2007). Therefore,
supplementing conventional systemic treatment with gene
therapy as a new approach to eradicate malignant cells might
be beneficial to cancer patients at all stages of the disease.
Transduction of a therapeutic transgene may induce a
persistent immune response to molecular characteristics of the
malignant phenotype. The most potent immunotherapeutic
approaches aim at the generation of tumor antigen-specific
cytotoxic T-lymphocytes (CTLs) (Pardoll and Allison, 2004).⁎ Corresponding author. Fax: +11 86 25 83724440.
E-mail address: jianqingwu@gmail.com (J.-Q. Wu).
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doi:10.1016/j.virol.2007.07.006Such immune responses require cross presentation of tumor
antigens by activated antigen-presenting cells (APCs), e.g.
dendritic cells (DCs) (Albert et al., 2001). To achieve activation
of naive tumor-specific CTLs, DCs have to undergo amaturation
process dependent on stimulation of CD40 by the CD40 ligand
(CD40L). Therefore, transduction of CD40L will be helpful in
the immunotherapy of tumor, such as lung carcinoma.
Actually, the concept of treating human diseases by intro-
ducing normal alleles of genes into appropriate target cells has
become a clinical reality. Although a variety of physical and
chemical methods have been developed for introducing exo-
genous DNA sequences into eukaryotic cells, viruses have
generally been proven to be much more efficient for this pur-
pose. Adeno-associated virus (AAV), a nonpathogenic human
parvovirus, has gained attention as a potentially safe vector for
gene transfer and gene therapy.
In the current study, we explore the most efficient serotype of
AAV in lung cancer A549 cells, and the potential effect of co-
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is frequently used in lung cancer chemotherapy. And we applied
the same serotype of self-complementary AAV (scAAV) vector,
expressing CD40L, to examine the effect of expression of
CD40L in A549 cells. The results indicate that scAAV2/5-
CD40L may provide an effective approach of therapy for lung
cancer.
Results
Transduction efficiency of different serotypes of AAV in A549
cells
AAV vectors transduce certain cell types, such as brain and
muscle, exceedingly well; however, controversies exist with
reference to their transduction efficiency in the lung. AAV2-
mediated cystic fibrosis transmembrane regulator (CFTR) gene
transfer into the human cystic fibrosis lung has been extensively
studied in clinical trials. However, CFTR gene expression in
these trials was sufficiently low to preclude the detection of
transgene-derived CFTR mRNA. AAV serotype 2 is the first
primate AAV to be cloned and the most extensively studied.
Recently, the identification of optimal AAV serotypes for a given
tissue target has been an area of intense interest in gene therapy
research. As we know, the availability of several additional AAV
serotype vectors, such as AAV1 through AAV10, has attracted
further attention; and their potential use as vectors in human
gene therapy is imminent (Grimm and Kay, 2003; Virella-
Lowell et al., 2005; Yan et al., 2000).
Transduction efficiency of AAV in A549 cells has not been
widely known. In our studies, the transduction efficiency of the
serotypes AAV2/1, AAV2/2, AAV2/5, AAV2/6, AAV2/7,
AAV2/8, AAV2/9 and AAV2/10 expressing green fluorescent
protein (GFP) in A549 cells was evaluated. A549 cells were
infected with different serotype AAV vectors at MOI of
104 particles/cell, the transduction efficiency was measured at
48 h post-infection. As shown in Fig. 1, compared to serotypes
AAV2/1, AAV2/2, AAV2/6, AAV2/7, AAV2/8, AAV2/9 and
AAV2/10, AAV2/5-mediated transgene expression was the
highest, which is consistent with Shi's report (Shi et al., 2005).
However, the transduction efficiency of all these serotypes
including the AAV2/5 was still low.
Transduction efficiency of scAAV2/5 in A549 cells
Shi et al. have reported that the transduction rate was ∼70%
in A549 when they were infected with AAV2/5. Our studies
suggested it was less than 20%. However, in Shi's studies, the
cells were infected at a very highMOI, whichwas 5×104. Such a
high MOI is infeasible in a clinical trial.
As we know, the AAV genome is a single-stranded DNA
(Berns and Giraud, 1996; Muzyczka, 1992), which is tran-
scriptionally inactive. Previous studies have suggested that viral
second-strand DNA synthesis is the rate-limiting step in AAV-
mediated transgene expression (Ferrari et al., 1996; Fisher et al.,
1996; Mah et al., 1998; Zhong et al., 2004). scAAV vectors,
which contain double-stranded genomes, and therefore bypassthe requirement for viral second-strand DNA synthesis, lead to a
significant increase in AAV-mediated transduction efficiency.
The human CD40L is a 39-kDa type II membrane glyco-
protein and its cDNA, which encodes a 261-amino-acids
CD40L, is 786 bp (Hollenbaugh et al., 1992). Based on our
previous studies, the maximum size of scAAV is ∼3.3 kb.
Apparently, it is suitable to use scAAV as a vector to deliver
CD40L cDNA.
To this aim, the scAAV2/5 containing a GFP expression
cassette was used to infect A549 cells. As expected, the trans-
duction efficiency of scAAV2/5 in A549 cells was significant
higher than that of conventional AAV2/5. The transduction
efficiency of scAAV2/5 in A549 cells was increased 3-fold,
compared to conventional AAV2/5 (Figs. 2A and B).
However, more effort to improve recombinant AAV (rAAV)
vector-mediated gene transfer and transgene expression is still
needed. Earlier studies suggested that AAV transduction could
be enhanced by gamma-irradiation, exposure to genotoxic
stress, and various chemotherapeutic agents (Kanazawa et al.,
2001; Zhao et al., 2006). Carboplatin is a chemotherapeutic
agent, which is used frequently in lung carcinoma, however, the
potential effect on AAV transduction efficiency has not been
reported.
Carboplatin enhances the AAV transduction in A549 cells
We next explored the potential effect of co-administration of
the chemotherapeutic agent carboplatin on AAV-mediated
transgene expression. To this end, A549 cells were pre-exposed
to 10 μg/ml carboplatin for 5 h before scAAV2/5 infection. This
concentration of carboplatin is similar to plasma peak levels
observed in pharmacokinetic studies. As shown in Figs. 2C and
D, A549 cells pretreated with the chemotherapeutic agent
carboplatin markedly increased AAV transgene expression
(∼8-fold), pb0.001. These results suggest that the combination
of conventional chemotherapy with gene therapy may enhance
the transduction of the therapeutic gene and will be beneficial to
eradicate lung cancer cells.
Transgene expression after transduction with
scAAV2/5/CD40L in A549 cells
Based on our above experiments, we delivered CD40L to
target A549 cells using scAAV2/5 as a vector. A549 cells were
mock (treated with serum-free media) or infected with scAAV2/
5/CD40L with or without carboplatin treatment at an MOI of
104 particles/cell. CD40L transgene expression in A549 cells
was analyzed 48 h after infection with scAAV2/5/CD40L by
Western blot and fluorescence-activated cell sorting (FACS). As
can be seen in Fig. 3A, with scAAV2/5/CD40L infection,
CD40L protein was expressed in A549 cells; and the expression
was enhanced by carboplatin pretreatment. As expected, the
FACS data demonstrated the percentage of CD40L positive cells
was ∼20% with scAAV2/5/CD40L infection. However, this
increased to 60% with carboplatin pretreatment (Fig. 3B).
Carboplatin increased the CD40L transgene expression ∼3-
fold, whereas it enhanced the GFP expression ∼8-fold. The
Fig. 1. (A) Comparative analysis of transduction efficiency of different serotypes of AAV in A549 cells. Original magnification: 100×. (B) Quantitative analysis of
transduction efficiency of different serotypes AAV in A549 cells. Images from three visual fields were analyzed quantitatively by ImageJ analysis software. Transgene
expression was assessed as total area of green fluorescence (pixel2) per visual field (mean±SD). ∗pb0.001, versus all other groups. ∗∗pb0.001 versus mock, AAV2/1,
AAV2/5, AAV2/7, AAV2/8, AAV2/9, AAV2/10. ∗∗∗pb0.001 versus mock, AAV2/5, AAV2/7, AAV2/8, AAV2/9, AAV2/10, pb0.01 versus AAV2/1.
311J.-Q. Wu et al. / Virology 368 (2007) 309–316difference is because the former measures the number of positive
cells by FACS while the latter measures total expression
fluorescence microscopy and ImageJ software.
Stimulation of DCs by co-cultivation with
scAAV2/5/CD40L-transduced A549 cells
To demonstrate functional gene transfer and provide the basis
for the development of an immunotherapeutic model system, the
immunostimulatory capacity of lung cancer A549 cells expres-
sing CD40L as a consequence of rAAV-mediated gene transfer
was investigated after co-cultivation of these cells with DCs. In
this experiment, A549 cells were also infected with scAAV2/5/
CD40L at an MOI of 104 particles/cell.Immature DCs were generated from isolated peripheral blood
mononuclear cells (PBMCs) as described by Banchereau using
granulocyte–macrophage colony-stimulating factor (GM-CSF)
and interleukin 4 (IL-4) as essential stimuli (Banchereau and
Steinman, 1998). Authenticity of the DCs was confirmed by
their typical morphology and flow cytometric assessment of up-
regulated cell surface determinants CD1a, CD80, CD86, MHC
class I, and MHC class II, all markers of the conversion of
monocyte precursors to immature DCs. Maturation to DCs that
are able to activate CTLs is associated with up-regulation of
antigen-presenting and co-stimulatory molecules including
soluble cytokines, such as interleukin 12 (IL-12). Co-cultivation
of transduced A549 cells with immature DCs resulted in their
release of substantial IL-12. Therefore, we measured the levels
Fig. 2. (A) Comparative analysis of transduction efficiency of conventional and self-complementary AAV2/5 in A549 cells. Original magnification: 100×. (B)
Quantitative analysis of conventional and self-complementary AAV2/5-mediated transgene expression in A549 cells. Images from three visual fields were analyzed
quantitatively by ImageJ analysis software. Transgene expression was assessed as total area of green fluorescence (pixel2) per visual field (mean±SD). ∗pb0.001,
versus mock and conventional AAV2/5. (C) Comparative analysis of transduction efficiency of scAAV2/5 with and without carboplatin in A549 cells. Original
magnification: 100×. (D) Quantitative analysis of conventional and scAAV2/5-mediated transgene expression in A549 cells. Images from three visual fields were
analyzed quantitatively by ImageJ analysis software. Transgene expression was assessed as total area of green fluorescence (pixel2) per visual field (mean±SD).
∗pb0.001, versus mock and scAAV2/5 without carboplatin pretreated.
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the immunostimulatory effect of CD40L was also confirmed by
pre-incubation of scAAV2/5/CD40L-transduced cells with a
monoclonal antibody binding to human CD40L. See Fig. 4.
Suppression of s.c. tumor growth
The s.c. model was employed (see Materials and methods) to
analyze the therapeutic potential of scAAV2/5-CD40L. Mon-itoring of tumor growth for 45 days revealed substantial growth
reduction in the scAAV2/5-CD40L-injected tumors, but not in
the scAAV2/5-GFP or PBS control groups. At the 45th day after
inoculation of the tumor cells, the tumor sizes and weights were
calculated. The tumor sizes and weights of the PBS-treated
group and the scAAV2/5-GFP control group were 0.76±
0.10 cm3 and 1.04±0.15 g and 0.81±0.14 cm3 and 1.09±
0.20 g, respectively. Compared with these control groups, the
tumor sizes and weights of the scAAV2/5-CD40L-treated group
Fig. 4. Co-incubation with AAV/CD40L-transduced A549 cells stimulates
dendritic cells to secrete interleukin 12 and the secretion was blocked by pre-
incubation with anti-CD40L. Immature dendritic cells were co-cultivated with
mock and scAAV2/5/CD40L-transduced lung cancer A549 cells. 48 h after co-
incubation, the release of interleukin 12 into the supernatant was measured by
ELISA. Production of IL-12 by human dendritic cells co-cultivated with
scAAV2/5/CD40L-transduced cells was significantly decreased by pre-incuba-
tion with anti-CD40L, a monoclonal antibody binding specially to the human
CD40L. mock: non-scAAV2/5/CD40L-transduced lung cancer A549 cells co-
cultivated with dendritic cells, ∗pb0.001, versus mock and scAAV2/5/CD40L
with pre-incubation with anti-CD40L.
Fig. 3. (A) Western blot analysis for the expression of CD40L. Lane 1: mock,
lane 2: scAAV2/5, lane 3: scAAV2/5+ carboplatin. (B) Transgene expression
after transduction with scAAV2/5/CD40L. A549 cells were mock or infected
with scAAV2/5 at MOI 104 particles/cell. Human CD40L expression was ana-
lyzed 48 h post-infection by flow cytometry. *pb0.001, versus Carboplatin(–).
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0.08 g, Pb0.001. There was no significant difference between
PBS-treated group and scAAV2/5-GFP control group, PN0.05.
The inhibition rate in the scAAV2/5-CD40L group was 66.8±
4.9%. Evidence to support tumor cell apoptosis was also
provided by terminal nucleotidyl transferase (TdT)-mediated
nick end labeling assays, demonstrating significantly higher
levels of apoptotic cell death in the scAAV2/5-CD40L group on
day 45 days. The apoptotic index of scAAV2/5-CD40L group
was significantly higher than the PBS-treated group (17.26±
2.50% vs. 6.32±1.10%, pb0.001), and there was no significant
difference between the PBS-treated group and the scAAV2/
5-GFP control group (6.50±0.99%, pN0.05).
Discussion
Transduction of a therapeutic transgene may induce a per-
sistent immune response to molecular characteristics of the
malignant phenotype. Expression of CD40L, a member of the
tumor necrosis factor protein family, in tumor cells has been
recognized as an effective strategy to evoke or enhance an anti-
tumor immune responses (Kikuchi and Crystal, 1999). DCs,
which are able to cross-present tumor-derived antigens after
uptake and processing, are considered the most important
professional APCs of the primary route of T-cell stimulation. An
optimal priming of tumor-specific CTLs requires the assistance
of CD4+ T-cells (Bennett et al., 1998; Schoenberger et al., 1998)
which seems to be dependent on the binding of CD40L to CD40.
Expression of CD40L in tumors facilitated the interaction
between DCs and the tumors, enhanced the maturation of DCs,
induced secretion of cytokines, and consequently produced
T-cell-dependent systemic immunity (Tada et al., 2003).The AAV vector is nonpathogenic, has minimal vector-
related toxicity, and induces a low host of cellular immune
response. Moreover, AAV2 vectors are currently in use in phase
I/II clinical trials for gene therapy for cystic fibrosis, hemophilia
B, α-1 anti-trypsin deficiency and neurological disorders
(Aitken et al., 2001; Flotte et al., 2004; Kay et al., 2000;
Manno et al., 2003; Wagner et al., 2002). To achieve better
efficacy of gene therapy for lung carcinoma, discovering the best
serotype of AAV vectors for gene delivery in lung cancer cells is
the first important step. For this purpose, we examined the
transduction efficiency of different serotypes of AAV 2/1, 2/2, 2/
5, 2/6, 2/7, 2/8, 2/9 and 2/10 vectors in the lung adenocarcinoma
A549 cell line. These results document that AAV2/5 was the
most robust to deliver the gene in A549 cells. However, the
transduction efficiency of AAV2/5 is still low.
Previous studies have suggested that viral second-strand
DNA synthesis is the rate-limiting step in AAV-mediated
transgene expression (Ferrari et al., 1996; Fisher et al., 1996;
Mah et al., 1998; Zhong et al., 2004). The scAAV vectors, which
bypass the requirement of viral second-strand DNA synthesis,
can increase the AAV transduction efficiency (McCarty et al.,
2001; Wang et al., 2003). Our current study suggests that
scAAV2/5 increased the transduction efficiency ∼3-fold,
compared with conventional AAV2/5, even though this increase
is still modest. Our results also indicated that AAV-mediated
gene transfer into lung cancer cells can be tremendously
enhanced by co-administration of carboplatin compounds used
in cancer chemotherapy. These observations provide the basis
for in vivo studies to confirm the positive effects of simul-
taneously administered chemotherapy on intratumoral gene
transfer.
Furthermore, as an initial step to prove the feasibility of a
concept of lung cancer treatment based on CD40L gene transfer
with AAV vectors, lung cancer cells were transduced with
scAAV/CD40L and co-incubated with human DCs that had been
314 J.-Q. Wu et al. / Virology 368 (2007) 309–316generated from PBMCs. Remarkably, substantial activation of
DCs, measured by IL-12 release, was achieved even when low
susceptibility of A549 lung cancer cell lines to AAV-mediated
transduction resulted in small fractions of transgene-expressing
cells. That IL-12 secretion could be blocked with a monoclonal
antibody binding to CD40L was indicative of a highly specific
effect. These data support a possible mechanism of the antitumor
responses: Tumor cells expressing CD40 can transcribe DCs-
derived cytokine genes by the expressed CD40L (Wada et al.,
2004).
Intratumoral transfer of CD40L-encoding DNA is considered
a promising strategy to achieve prolonged activation of DCs in
vivo leading to stronger immune responses by triggering CD8+
T-cells. Immune stimulation with DCs-based vaccines on the
other hand apparently can not give rise to a long-lasting state of
DCs activation with prolonged stimulation of T cells by secreted
cytokines (Langenkamp et al., 2000). For intratumoral gene
transfer in different murine cancer model systems, adenoviral
vectors have successfully been used to express CD40L (Kikuchi
and Crystal, 1999; Loskog et al., 2004). AAV-derived vectors are
an attractive alternative to adenoviral systems in view of the fact
that prolonged transgene expression can be achieved without
induction of inflammation or an anti-AAV immune response.
The capacity of the derived CD40L transgenic tumor cells to
stimulate co-cultivated DCs was indicated by a substantial
release of IL-12. The possible mechanism in part responsible for
the observed effects of scAAV2/5-CD40L on the implanted
tumor growth and apoptosis may be that local expression of
CD40L on tumor cells via an amplicon vector would activate
recruited DCs. These results underline the potential of rAAV-
based gene therapy of lung cancer and provide a solid basis for
future clinical trials. However, parallel to the generation of
tumor-specific AAV derivatives, intratumoral AAV-mediated
CD40L gene transfer needs to be further studied in vivo to
provide a solid basis for future clinical studies.
In summary, we have shown that so far AAV2/5 is the most
efficient serotype vector for gene transduction in A549 cells. The
efficiency of scAAV2/5-mediated gene transfer into A549 lung
cancer cells is significantly higher than that of conventional
AAV, and it can be further enhanced by co-administration of a
chemotherapeutic agent. As a basis for future immunotherapeu-
tic approaches including intratumoral transfer of stimulating
factors, we also confirmed that lung cancer cells infected with a
CD40L-encoding AAV can activate human DCs to secrete IL-
12, and intratumoral administration of scAAV2/5-CD40L can




The human lung adenocarcinoma cell line A549 was
maintained at 37 °C in a 5% CO2 atmosphere in RPMI 1640
media supplemented with 10% fetal bovine serum and 1% (by
volume) 100× stock solution of antibiotics (10,000 U of
penicillin plus 10,000 μg of streptomycin).To generate human DCs, PBMCs were isolated by centrifu-
gation in a Ficoll density gradient and enrichment of monocytes
was achieved by an adherence step as described previously
(Koppold et al., 2005). To generate DCs, the isolated monocytes
were transferred to 6-well plates and cultured in RPMI 1640
supplemented with 10% heat-inactivated human AB serum,
penicillin/streptomycin, and 100 U/ml heparin. After 8 h, re-
combinant human GM-CSF and IL-4 were added. These factors
were renewed after 3 days. Monocytes and DCs were immuno-
phenotyped with a set of monoclonal antibodies binding to
CD1a, CD14, CD86, CD206, MHC-I and MHC-II. These anti-
bodies were conjugated with fluorescein isothiocyanate (FITC),
phycoerythrin (PE) or phycoerythrin cyanine 5 (PE- Cy5) and
were from BD Pharmigen company.
Animals
Female 5- to 6-week-old BALB/c nude mice were housed at a
constant temperature and supplied with laboratory chow and
water on a 12-h dark/light cycle in specific pathogen-free
conditions.
Construction, production and measurement of titers of the
rAAV vectors
Standard cloning techniques were used for constructing all
recombinant plasmids. To construct plasmids pCMV-CD40L,
which are conventional AAV vectors containing human
CD40L cDNA, pAAV-hrGFP was digested with Sac I/Rsr I
and ligated with the CD40L cDNA fragment. To construct
plasmids pdsAAV–CMV–CD40L, which are scAAV vectors
containing human CD40L cDNA, pJW3 was digested with
Sac I and ligated with the CD40L cDNA fragment. All
vectors and inserts were treated with the Klenow fragment of
Italicize Escherichia coli DNA polymerase I and then blunt-
end-ligated.
rAAV vectors were produced using the calcium phosphate
triple-plasmid transfection protocol (Zhao et al., 2006). All
recombinant vectors were purified using the CsCl density
gradient method. The titers of DNA-containing viral particles
were determined by quantitative DNA slot blot.
rAAV vector-mediated transduction assays
Approximately 1.5×105 A549 cells were plated in each well
in 12-well plates and incubated at 37 °C for 18 h. Cells were
washed once with serum-free media and then either mock-
infected or infected with AAV vectors at a multiplicity of
infection (MOI) of 1×104 particles/cell. 48 h post-infection,
cells were observed under a Zeiss Axiovert 25 fluorescence
microscope (Carl Zeiss, Inc., Thornwood, NY). The viral trans-
duction efficiency was measured by GFP imaging using images
from three visual fields of mock-infected and vector-infected
cells 48 h post-infection and analyzed quantitatively by ImageJ
analysis software (NIH, Bethesda, MD). Transgene expression
was assessed as total area of green fluorescence (pixel2) per
visual field (mean±SD).
315J.-Q. Wu et al. / Virology 368 (2007) 309–316To evaluate the potential effect of the chemotherapeutic agent
carboplatin on AAV transduction efficiency, A549 cells were
plated and incubated 18 h, and before infection, the cells were
treated with 10 μg/ml carboplatin for 5 h. After incubation of
cells with carboplatin, cells were washed once with serum-free
media and then infected with AAV vectors.
To determine AAV-mediated expression of the human
CD40L, whole cell extracts (WCEs) were prepared (Zhao et
al., 2006). Total protein concentrations were determined using
the Bio-Rad protein assay kit, and 40 μg of protein was separated
by SDS–polyacrylamide gel electrophoresis on a 10% poly-
acrylamide gel. After transfer to an Immobilon-P membrane
(Millipore, Bedford, MA), the membrane was blocked at 25 °C
for 1 h with 5% nonfat dry milk in 1× Tris-buffered saline (TBS),
and 0.05% Tween 20, then incubated with a 1:500 dilution of
anti-CD40L antibody for 1 h at 25 °C. Following incubation
with 1:5000 dilution of horseradish peroxidase-coupled anti-
rabbit IgG antibody for 1 h at 25 °C, protein bands were
visualized with the ECL-Plus chemiluminescence detection kit
(Amersham Biosciences, Piscataway, NJ). Cells were also
harvested 48 h post-infection and analyzed by FACS. Briefly,
cells were washed twice with washing buffer (PBS containing
10% fetal bovine serum). For FACS, cells were resuspended in
80 μl washing buffer, then 0.5–1.0 μg phycoerythrin (PE)-
conjugated monoclonal antibody specific for CD40L (BD
Pharmingen) was added and incubated for 20 min. Then cells
were washed twice with 2-ml washing buffer and resuspended in
0.5 ml PBS for analysis by FACS. PE-labeled hamster IgG3
isotype was used as control antibody.
Activation of DCs co-cultivation with CD40L transgenic A549
cells
The potential of CD40L-transgenic A549 cells to activate
DCs was analyzed by co-incubation of similar numbers of both
cell types for 48 h. Secretion of IL-12 was measured with an
immunoassay (BD Pharmingen) specific for IL-12. To specifi-
cally block activation of DCs mediated by transgenic CD40L,
we used a monoclonal antibody binding to human CD40L.
S.c. tumor xenografts and assessment of growth
A549 cells (1×107) were administered in the s.c. tissue of the
right flank of BALB/c nude mice. Tumor growth was monitored
regularly and volume (V) was calculated using the formula
V=1/2× length×(width)2. When tumor size reached ∼50 mm3
(about 14 days post-inoculation), animals were randomized into
three groups (in each group, n=5) and vectors were ad-
ministered by intratumoral injection. Groups 1 and 2 received
2×1011 particles scAAV2/5-CD40L or scAAV2/5-GFP, respec-
tively; and group 3 mice received PBS as control. Mice were
sacrificed 45 days after tumor cell implantation. The inhibitory
rate (IR) was calculated using the formula, IR=(1−mean tumor
weight of the treated group /mean tumor weight of the control
group)×100%. Apoptosis was measured by TUNEL, and the
apoptotic index (AI) was calculated using the formula,
AI=number of the apoptotic cells / number of the total cellswhich will be observed, and the total cells which were observed
was not less than 1000 cells.
Statistical analysis
All data are reported as mean±standard error. One way
ANOVA was used to evaluate statistical significance by
SigmaStat software. P values were considered to be statistically
significant when b0.05.
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